Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLRX 
Pliant Therapeutics Inc (PLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: PLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.79
1 Year Target Price $4.79
| 1 | Strong Buy |
| 1 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.8% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.33M USD | Price to earnings Ratio - | 1Y Target Price 4.79 |
Price to earnings Ratio - | 1Y Target Price 4.79 | ||
Volume (30-day avg) 13 | Beta 1.36 | 52 Weeks Range 1.10 - 16.10 | Updated Date 07/16/2025 |
52 Weeks Range 1.10 - 16.10 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.89% | Return on Equity (TTM) -63.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -156460897 | Price to Sales(TTM) 3071.82 |
Enterprise Value -156460897 | Price to Sales(TTM) 3071.82 | ||
Enterprise Value to Revenue 1376.69 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 61386300 | Shares Floating 54119370 |
Shares Outstanding 61386300 | Shares Floating 54119370 | ||
Percent Insiders 3.04 | Percent Institutions 101.02 |
Upturn AI SWOT
Pliant Therapeutics Inc
Company Overview
History and Background
Pliant Therapeutics, Inc. was founded in 2015. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics for fibrotic diseases.
Core Business Areas
- Integrin Program: Development of small molecule integrin inhibitors to target fibrotic diseases.
- Thrombospondin-1 (TSP1) Program: Development of therapeutics targeting TSP1 pathways for fibrotic diseases.
Leadership and Structure
Dr. Bernard Coulie is the President and CEO. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Bexotegrast: An oral, selective inhibitor of u03b1vu03b26 integrin. It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). There is no revenue from this product yet as it is in clinical development. Competitors include Boehringer Ingelheim and Roche.
Market Dynamics
Industry Overview
The industry focuses on developing therapies for fibrotic diseases, characterized by excessive scar tissue formation. This is a growing market due to the increasing prevalence of these diseases.
Positioning
Pliant Therapeutics is positioned as an innovative company developing novel small molecule therapeutics targeting integrins to address unmet needs in fibrotic diseases.
Total Addressable Market (TAM)
The TAM for fibrotic disease therapies is estimated to be in the billions of dollars. Pliant Therapeutics aims to capture a significant share by offering targeted therapies with potentially improved efficacy and safety profiles.
Upturn SWOT Analysis
Strengths
- Novel integrin-targeting platform
- Strong preclinical and clinical data
- Experienced management team
- Partnerships with leading research institutions
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Limited revenue streams
Opportunities
- Expanding pipeline to address other fibrotic diseases
- Potential for breakthrough therapies
- Strategic collaborations with pharmaceutical companies
- Positive clinical trial results driving market value
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- GILD
- NVO
Competitive Landscape
Pliant is competitive due to its novel small molecule approach targeting integrins, while large pharmaceutical companies have greater resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by the advancement of clinical trials and potential indication expansion.
Future Projections: Future growth depends on the success of Bexotegrast and other pipeline assets in clinical trials.
Recent Initiatives: Initiatives focus on advancing clinical trials for Bexotegrast in IPF and PSC and expanding the pipeline.
Summary
Pliant Therapeutics is a clinical-stage biotech company with a novel approach to treating fibrotic diseases. Its strengths lie in its innovative technology and experienced team, while its weaknesses include being pre-revenue and reliant on clinical trial success. Opportunities include expanding the pipeline and strategic partnerships, while threats include clinical trial failures and competition. The company's success is closely tied to the clinical development of Bexotegrast and other pipeline assets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The analysis is based on publicly available information and represents an opinion. It is not financial advice. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pliant Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-06-03 | President, CEO & Director Dr. Bernard Coulie M.B.A., M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 171 | Website https://pliantrx.com |
Full time employees 171 | Website https://pliantrx.com | ||
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.